Get the Daily Brief
Latest Biotech News
Eli Lilly Opens AI Platform TuneLab to Biotechs for Drug Discovery Collaboration
Eli Lilly launched TuneLab, an AI platform granting early-stage biotech companies access to Lilly’s drug discovery models trained on decades of data. Participating biotechs contribute their own...
AI Model PDGrapher Identifies Treatments That Reverse Disease States
Harvard Medical School researchers developed PDGrapher, an AI-driven neural network that identifies gene targets capable of reversing diseased cellular states. Unlike traditional single-target...
Small Cell Lung Cancer Exploits Neuronal Synapses to Enhance Growth
Researchers uncovered that small cell lung cancer (SCLC) cells form functional synaptic connections with neurons both in the lung and brain metastases, integrating electrophysiologically into...
Novel Non-neutralizing Antibody Cocktail Shows Broad Flu Protection in Mice
Scientists at Jackson Laboratory developed a cocktail of non-neutralizing antibodies targeting overlapped epitopes of influenza A matrix protein, providing broad protection against diverse...
Breakthrough Single-Cell Atlas Illuminates Human Atherosclerosis Complexity
Researchers unveiled the first integrated single-cell atlas of human atherosclerotic plaques, revealing cellular heterogeneity and molecular pathways underpinning this leading cause of...
J&J’s Inlexzo Gains FDA Approval, Offering New Bladder Cancer Treatment Option
The FDA approved Johnson & Johnson’s Inlexzo, an intravesical gemcitabine-releasing device for patients with BCG-unresponsive, non-muscle invasive bladder cancer. The device delivers chemotherapy...
Novartis Acquires Tourmaline Bio for Cardiovascular Inflammation Drug
Novartis finalized a $1.4 billion acquisition of Tourmaline Bio, gaining its lead asset pacibekitug, an anti-IL-6 monoclonal antibody for treating atherosclerotic cardiovascular disease (ASCVD)....
J&J’s Inlexzo Approved for Non-Muscle Invasive Bladder Cancer
The FDA granted approval for Johnson & Johnson’s Inlexzo, an intravesical device releasing gemcitabine for patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder...
Breakthrough AI Model Identifies Treatments to Reverse Disease States
Researchers at Harvard Medical School unveiled PDGrapher, a novel artificial intelligence model that simultaneously identifies therapeutic targets most likely to reverse diseased cellular states...
Merck Ends UK Research Operations Over Policy Frustrations
Merck halted all discovery research operations in the United Kingdom and canceled plans for a £1 billion London drug research center, citing the government’s insufficient life sciences investments...
Decade’s Most Precise Gravitational Wave Confirms Black Hole Theories
The LIGO-Virgo-KAGRA Collaboration’s detection of GW250114 delivered the clearest gravitational wave signal to date from a binary black hole merger, providing direct confirmation of Stephen...
New Antibody Therapy Shows Broad Protection Against Influenza Strains
Scientists at the Jackson Laboratory developed a cocktail of non-neutralizing antibodies targeting conserved epitopes on influenza A virus’s matrix protein 2 ectodomain, conferring broad...
Lucid Diagnostics Plans $25 Million Public Offering Ahead of Medicare Coverage
Lucid Diagnostics announced a public offering of 25 million shares at $1 each, aiming to raise approximately $25 million to support working capital and corporate purposes. The sequencing-based...
Cancer and Immune System Interactions Reveal New Lung Tumor Insights
Multiple studies presented at recent lung cancer conferences unveil groundbreaking discoveries in tumor-immune interactions. Research from Stanford Medicine and the Icahn School of Medicine at...
Eli Lilly Opens AI Platforms to Accelerate Biotech Drug Discovery
Eli Lilly launched TuneLab, a new AI platform offering drug discovery models trained on decades of Lilly research for use by selected biotechs at no cost. The initiative aims to leverage federated...
Noa Therapeutics and Johns Hopkins Advance Novel Immune Modulating Treatment
Noa Therapeutics received a Catalyst Research Grant from the National Eczema Association to fund preclinical evaluations of its lead biased aryl hydrocarbon receptor (AhR) drug candidate at Johns...
Novartis Acquires Tourmaline Bio for $1.4 Billion to Boost Cardiovascular Pipeline
Novartis announced the acquisition of Tourmaline Bio for $1.4 billion, gaining rights to pacibekitug, an anti-IL-6 monoclonal antibody targeting atherosclerotic cardiovascular disease (ASCVD)....
FDA Approval of J&J’s Drug-Device Combo Inlexzo Offers New Bladder Cancer Option
Johnson & Johnson received FDA approval for Inlexzo (formerly TAR-200), a drug-device system releasing gemcitabine into the bladder to treat Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle...
Harvard’s AI Model PDGrapher Identifies Combinatorial Treatments to Reverse Disease States
Researchers at Harvard Medical School developed PDGrapher, an AI model that predicts gene targets capable of reverting diseased cells to healthy states by analyzing multiple disease drivers...
Breakthroughs in Cancer Therapies: Antibody–Bottlebrush Prodrugs and Immunotherapy Advances
MIT chemists introduced antibody–bottlebrush prodrugs that enable higher drug loads and payload diversity compared to traditional antibody-drug conjugates (ADCs), showing favorable preclinical...